New CEO at Evaxion

Evaxion A/S has appointed Helen Tayton-Martin, a board member, as chief executive officer, effective 24 November. A co-founder of Adaptimmune, Dr Tayton-Martin brings 30 years of experience in biotech company building, fund raising, M&A, business development and operations. She was chief operating officer and later chief business & strategy officer during her 17 years at Adaptimmune. Evaxion’s interim CEO Birgitte Rønø will continue in her role as chief scientific officer. Dr Tayton-Martin is stepping down from Evaxion’s board. Jens Bitsch-Norhave, who has more than 25 years in the biotech and pharmaceutical industry, will join as observer and advisor to the board with the intention of seeking election at Evaxion’s next annual general meeting.

Evaxion announced the appointment on 28 October 2025.